

Tuberculosis profile: Democratic People's Republic of Korea

Population 2021: 26 million

Estimates of TB burden*, 2021

	Number	(Rate per 100 000 population)
Total TB incidence	133 000 (114 000-153 000)	513 (441-590)
HIV-positive TB incidence		
MDR/RR-TB incidence**	5 300 (1 300-9 200)	20 (5.1-35)
HIV-negative TB mortality		
HIV-positive TB mortality		

Estimated proportion of TB cases with MDR/RR-TB*, 2021

New cases	2.5% (0.96-5.4)
Previously treated cases	12% (3.3-31)

Universal health coverage and social protection*

TB treatment coverage (notified/estimated incidence), 2021	66% (57-76)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2021	17% (12-23)

TB case notifications, 2021

Total new and relapse	87 413
- % tested with rapid diagnostics at time of diagnosis	
- % with known HIV status	0%
- % pulmonary	80%
- % bacteriologically confirmed ^	48%
- % children aged 0-14 years	5%
- % women (aged ≥15 years)	35%
- % men (aged ≥15 years)	60%
Total cases notified	93 597

TB/HIV care in new and relapse TB patients, 2021

	Number	(%)
Patients with known HIV status who are HIV-positive	0	
- on antiretroviral therapy	0	

Drug-resistant TB care**, 2021

% of bacteriologically confirmed TB cases tested for rifampicin resistance - New cases ^	0%
% of bacteriologically confirmed TB cases tested for rifampicin resistance - Previously treated cases ^	3.6%
Laboratory-confirmed cases - MDR/RR-TB ^^	270
Patients started on treatment - MDR/RR-TB ^^	815
Laboratory-confirmed cases - pre-XDR-TB or XDR-TB ^^	0
Patients started on treatment - pre-XDR-TB or XDR-TB ^^	0
MDR/RR-TB cases tested for resistance to any fluoroquinolone	0

Treatment success rate and cohort size

	Success	Cohort
New and relapse cases registered in 2020	87%	89 640
Previously treated cases, excluding relapse, registered in 2020	76%	8 729
HIV-positive TB cases registered in 2020		0
MDR/RR-TB cases started on second-line treatment in 2019	72%	2 312
Pre-XDR-TB/XDR-TB cases started on second-line treatment in 2019	79%	84


TB preventive treatment, 2021

% of HIV-positive people (newly enrolled in care) on preventive treatment	
% of children (aged < 5 years) household contacts of bacteriologically-confirmed TB cases on preventive treatment	99% (91-100)


Funding for TB

Funding for TB, 2021 (US\$ millions)	9
- % domestic funding	83%
- % international funding	17%


Incidence, New and relapse TB cases notified, HIV-positive TB incidence (Rate per 100 000 population per year)




HIV-negative TB mortality (Rate per 100 000 population per year)




Incidence, Notified cases by age group and sex, 2021 (Number)



Cases attributable to five risk factors, 2021 (Number)



Funding for TB (US\$ millions)



** Estimates of TB burden are produced by WHO in consultation with countries. Ranges represent uncertainty intervals.*
*** RR is TB resistant to rifampicin (R); MDR is TB resistant to R + isoniazid; pre-XDR is TB resistant to R + any fluoroquinolone*
^ Calculated for pulmonary cases only
^^ Includes cases with unknown previous TB treatment history
^^^ Includes patients diagnosed before 2021 and patients who were not laboratory-confirmed